Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).

被引：0
|
作者：
Rebuzzi, Sara Elena
Bauckneht, Matteo
Signori, Alessio
Frantellizzi, Viviana
Rizzini, Elisa Lodi
Mascia, Manlio
Lavelli, Valentina
Stazza, Maria Lina
Licari, Maria
Donegani, Maria Isabella
Ponzano, Marta
Cavallini, Letizia
Laghi, Viola
Cindolo, Luca
Costa, Renato Patrizio
Spanu, Angela
Rubini, Giuseppe
Monari, Fabio
De Vincentis, Giuseppe
Fornarini, Giuseppe
机构：
[1] Univ Genoa, Med Oncol Unit 1, IRCCS Osped Policlin San Martino, Dept Internal Med & Med Specialties DiMI, Genoa, Italy
[2] IRCCS Osped Policlin San Martino, Nucl Med Unit, Genoa, Italy
[3] Sapienza Univ Rome, Dept Mol Med, Rome, Italy
[4] IRCCS Azienda Osped Univ Bologna, Radiat Oncol, Bologna, Italy
[5] Spirito Santo Hosp, Nucl Med Unit, Pescara, Italy
[6] Univ Bari Aldo Moro, Dept Nucl Med, Bari, Italy
[7] Univ Sassari, Dept Med Surg & Expt Sci, Nucl Med Unit, Sassari, Italy
[8] Univ Palermo, Biomed Dept Internal & Specialist Med, Nucl Med Unit, Palermo, Italy
[9] Univ Genoa, Dept Hlth Sci DISSAL, IRCCS Osped Policlin San Martino, Nucl Med, Genoa, Italy
[10] Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy
[11] Alma Mater Studiorum Bologna Univ, Dept Expt Diagnost & Specialty Med, IRCCS Azienda Osped Univ Bologna, Radiat Oncol, Bologna, Italy
[12] Villa Stuart Private Hosp, Dept Urol, Rome, Italy
[13] Sapienza Univ Rome, Dept Radiol Sci Oncol & Anat Pathol, Rome, Italy
[14] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17026
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study
    Song, Daniel Y.
    George, Saby
    Zimberg, Shawn
    Nordquist, Luke T.
    Tomaszewski, Jeffrey
    Conti, Peter S.
    Meltzer, Jeffrey
    Verholen, Frank
    Schmall, Anja
    Higano, Celestia S.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Osteonecrosis of the jaw (ONJ) in radium 223 (Ra223)-treated metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with exposure to zoledronic acid and/or denosumab.
    Cao, Yen Thi Kim Hong
    Trieu, Janson
    Rojas, Vanessa
    Elias, Michael
    Anderson, Michael J.
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study
    Angusti, Tiziana
    Di Stefano, Rosario F.
    Parente, Antonella
    Bungaro, Maristella
    Turco, Fabio
    Samuelly, Alessandro
    Pisano, Chiara
    Scagliotti, Giorgio, V
    Di Maio, Massimo
    Tucci, Marcello
    Buttigliero, Consuelo
    MINERVA UROLOGY AND NEPHROLOGY, 2022, 74 (06): : 703 - 713
  • [44] Radium-223 (Ra-223) Re-treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC)
    Procopio, G.
    Severi, S.
    Verzoni, E.
    Sansovini, M.
    Sartor, O.
    Heinrich, D.
    Mariados, N.
    Mendez Vidal, M. J.
    Keizman, D.
    Thellenberg-Karlsson, C.
    Pe'er, A.
    Frank, S. J.
    Pulkkanen, K.
    Trigo Perez, J. M.
    Nordquist, L. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Miller, K.
    Heinrich, D.
    O'Sullivan, J. M.
    Carles, J.
    Wirth, M.
    Nilsson, S.
    Huang, L.
    Kalinovsky, J.
    Heidenreich, A.
    Saad, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 287 - 287
  • [46] Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (04) : 9 - 10
  • [47] Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study
    O'Sullivan, J.
    Heinrich, D.
    Marcos, E. Castro
    George, S.
    Song, D. Y.
    Dizdarevic, S.
    Baldari, S.
    Essler, M.
    de Jong, I. J.
    Lastoria, S.
    Hammerer, P. G.
    Tombal, B.
    James, N. D.
    Verholen, F.
    Meltzer, J.
    Sandstroem, P.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1181 - S1181
  • [48] First interim results of the Radium-223 (Ra-223) reassure observational study in metastatic castration-resistant prostate cancer (mCRPC): Safety and baseline (BL) characteristics of US patients (Pts) by prior/concomitant treatment (Tx).
    Harshman, Lauren Christine
    Sartor, A. Oliver
    Richardson, Timothy
    Sylvester, John
    Song, Daniel Y.
    Mantz, Constantine
    Brookland, Robert K.
    Perlmutter, Mark
    Given, Robert
    Kalinovsky, Jan
    Babajanyan, Svetlana
    De Sanctis, Yoriko
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC).
    Sartor, A. Oliver
    Heinrich, Daniel
    Mariados, Neil
    Jose Mendez-Vidal, Maria
    Keizman, Daniel
    Thellenberg-Karlsson, Camilla
    Peer, Avivit
    Procopio, Giuseppe
    Frank, Stephen Jay
    Pulkkanen, Kalevi
    Severi, Stefano
    Trigo Perez, Jose Manuel
    Schwarzenberger, Paul
    Li, Rui
    Nordquist, Luke T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [50] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A-K
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
12345